Amivantamab
Sources
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT05074940
Amivantamab in ACC, registry NCT05074940, results posted 05.08.2026 (registry; opened 2026-10-27): n 21; ORR 1 participant; median PFS 4.6 months; serious AEs 7 of 21; FACT-HN quality of life change -0.7 (reference point not stated).
Brief source A28
registry, as of 2026-11-07
https://clinicaltrials.gov/study/NCT05074940
Phase II Study to Evaluate Amivantamab in Recurrent and Metastatic Adenoid Cystic Carcinoma
ClinicalTrials.gov API v2 record, retrieved 2026-11-07